This record was last updated October 16, 2024 (before its estimated November 11, 2024 completion). Its status may not reflect the trial's current state.
Summary
The primary purpose of the study is to evaluate the efficacy and safety of APHD-012 (distal jejunal-release dextrose \[Aphaia technology, AT\]) in obese participants.
Protocol Amendment History
3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-05-20; most recent amendment 2024-10-14.
Status change: Recruiting → Active, Not Recruiting2024-10-14
Status change: Not Yet Recruiting → Recruiting2023-01-10